

Product Information

MONOCLONAL ANTI-GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) CLONE G-A-5 Cy3 CONJUGATE Purified Mouse Immunoglobulin

Product No. **C9205**

Product Description

Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) conjugated to Cy3 is a purified mouse monoclonal antibody conjugated to Cy3 reactive dye.¹ Monoclonal Anti-Glial Fibrillary Acidic Protein (mouse IgG1 isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Purified GFAP from pig spinal cord was used as the immunogen.² The isotype is determined using Sigma ImmunoType™ Kit (Product Code ISO-1) and by a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents (Product Code ISO-2). The Cy3-antibody conjugate is extensively dialyzed to remove unbound Cy3.

Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) - Cy3 Conjugate reacts with the 50 kDa intermediate filament protein, GFAP, in brain and spinal cord, but not with other intermediate filaments. The epitope recognized by Monoclonal Anti-GFAP is localized on the carboxy terminal Cys II fragment of GFAP and the N-terminal part of the tail sequence of the molecule.^{2,3} The antibody has a broad cross-species reactivity, e.g. human, pig, cat, rat, chicken (not in Bergmann glia), goldfish, octopus and snail. The epitope recognized by the antibody is partially sensitive to prolonged formalin-fixation,⁴ but is resistant to alcohol-fixation followed by paraffin-embedding and to acetone-fixation of frozen sections.

Monoclonal Anti-Glial Fibrillary Acidic Protein - Cy3 Conjugate may be used for:

1. Identification of astrocytes and glia-related neoplasms.
2. Prenatal detection of astrocytes in cultured cells, e.g. from amniotic fluids of pregnancies with neural tube defects.
3. Screening of chemicals for neurotoxic effects in animals.
4. Studies of post-traumatic gliosis.
5. Developmental studies.
6. The conjugate may be applied in double labeling experiments with fluorescein-tagged antibodies.

In the central nervous system, GFAP is found in developing, normal, reactive and neoplastic astrocytes and ependymal cells.^{1,5-10} It is expressed in developing oligodendrocytes in the peripheral nervous system. GFAP is found in some Müller glia of the retina, Schwann cells, enteric glial cells and the satellite cells of human sensory ganglia. It has been demonstrated in some non-glial cells such as human salivary gland duct cells, adenohypophyseal folliculo-stellate cells, interstitial cells of the pineal gland, in a minor sub-population of breast myoepithelial cells,¹¹ elastic cartilage cells and perichondrial cells,¹⁰ but not in neurons. GFAP is expressed in several glial-related intracranial neoplasms such as astrocytomas (especially in the well-differentiated variety) and to a variable extent in ependymomas, medulloblastomas, choroid plexus papillomas, gangliogliomas, mixed gliomas, hemangioblastomas, pineocytomas, pineoblastomas, pituitary adenomas, retinoblastomas, oligodendrogliomas and in a small minority of peripheral nerve sheath tumors (schwannomas and neurofibromas). It may also be found in pleomorphic adenomas and ovarian and testicular teratomas.

Reagents

The conjugate is provided as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% BSA with 15 mM sodium azide as preservative.

Precautions and Disclaimer

Due to the sodium azide content a material safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazards and safe handling practices.

Product Profile

A minimum working dilution of 1:400 was determined by direct immunofluorescent staining of alcohol-fixed, paraffin-embedded rat cerebellum.

In order to obtain best results, it is recommended that each user determine the optimal working dilution for individual applications by titration assay.

Spectral Characteristics of Cy3

Absorbance Max 552 nm

Emission Max 570 nm

F/P Molar Ratio: 3 to 9

The F/P molar ratio of the antibody-Cy3 conjugate is determined spectrophotometrically as follows:

$$F = A_{552}/0.14 \quad P = \frac{A_{280} - (A_{552} \times 0.05)}{1.4}$$

F/P Molar Ratio = F/P x 0.16

Where:

0.14 = extinction coefficient of Cy3 at A_{552} .

1.4 = extinction coefficient of IgG at A_{280} .

0.05 = correction factor for Cy3 absorbance at A_{280} .

0.16 = correction factor for molecular weights of Cy3 and IgG.

Storage/Stability

Store at 2-8 °C. Protect from prolonged exposure to light. Do not freeze. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

References

1. Southwick, P., et al., Cytometry, **11**, 418 (1990).
2. Debus, E., et al., Differentiation, **25**, 193 (1983).
3. Shaw, G., and Hawkins, J., Neuro Report, **3**, 461 (1992).
4. Viale, G., et al., Am. J. Pathol., **133**, 369 (1988).
5. Altmannsberger, M., et al., Lab. Invest., **46**, 520, (1982).
6. Osborn, M., and Weber, K., Cell, **31**, 303 (1982).
7. Osborn, M., and Weber, K., Lab. Invest., **48**, 372 (1983).
8. Lazarides, E., Ann. Rev. Biochem., **51**, 219 (1982).
9. Geisler, N., and Weber, K., EMBO J., **2**, 2059 (1983).
10. Achstätter, T., and Moll, R., et al., Differentiation, **31**, 206 (1986).
11. Viale, G., et al., Virch. Arch. A. Pathol. Anat., **418**, 339 (1991).

Cy is a trademark of Amersham Life Science, Inc. Distributed under license from Amersham Life Science, Inc.

PCS/03

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications.

Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply.

Please see reverse side of the invoice or packing slip.